

Clinical Policy: Meloxicam Capsule

Reference Number: CP.CPA.296

Effective Date: 11.16.16

Last Review Date: 11.24

Line of Business: Commercial

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Meloxicam is a non-steroidal anti-inflammatory drug (NSAID).

FDA Approved Indication

Meloxicam is indicated for the management of osteoarthritis (OA) pain.

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

This policy is applicable to meloxicam 5 mg and 10 mg capsules. It is the policy of health plans affiliated with Centene Corporation[®] that meloxicam is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Osteoarthritis or Rheumatoid Arthritis Pain (off-label) (must meet all):

1. Diagnosis of OA or rheumatoid arthritis;
2. Age \geq 18 years;
3. Request is for meloxicam 5 mg and 10 mg capsules;
4. Failure of both of the following (a and b) at up to maximally indicated doses, unless clinically significant adverse effects are experienced or all are contraindicated:
 - a. Generic meloxicam tablet;
 - b. One other preferred NSAID (*See Appendix B*);
5. Dose does not exceed 10 mg per day.

Approval duration: 12 months or duration of request, whichever is less

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial; or

2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial.

II. Continued Therapy

A. Osteoarthritis or Rheumatoid Arthritis Pain (off-label) (must meet all):

1. Member meets one of the following (a or b):
 - a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
 - b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B*);
2. Member is responding positively to therapy;
3. If request is for a dose increase, new dose does not exceed 10 mg per day.

Approval duration: 12 months or duration of request, whichever is less

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial.

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off-label use policy – CP.CPA.09 or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key:

CABG: coronary artery bypass graft

FDA: Food and Drug Administration

NSAID: non-steroidal anti-inflammatory drug

OA: osteoarthritis

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
meloxicam (Mobic [®])	7.5 mg -15 mg PO QD	15 mg/day
diclofenac sodium (Voltaren [®])	50 mg PO TID	150 mg/day
etodolac (Lodine [®])	400 - 500 mg PO BID	1,200 mg/day
fenoprofen (Nalfon [®])	200 mg PO Q4-6 hr	3,200 mg/day
ibuprofen (Motrin [®])	400 - 800 mg PO Q6-8 hr	3,200 mg/day
indomethacin (Indocin [®])	25 - 50 mg PO BID-TID	200 mg/day
indomethacin SR (Indocin [®] SR)	75 mg PO QD - BID	150 mg/day
ketoprofen (Orudis [®])	25-75 mg PO Q6-8 hr	300 mg/day
meclofenamate (Meclomen [®])	50 - 100 mg PO Q4-6 hr	400 mg/day
naproxen (Naprosyn [®])	250 - 500 mg PO BID	1,500 mg/day
naproxen sodium (Anaprox [®] , Anaprox DS [®])	275 - 550 mg PO BID	1,650 mg/day
oxaprozin	600 - 1,200 mg PO QD	1,800 mg/day
piroxicam (Feldene [®])	10 - 20 mg PO QD	20 mg/day
salsalate (Disalcid [®])	500 - 750 mg PO BID-TID	3,000 mg/day
sulindac (Clinoril [®])	150 mg - 200 mg PO BID	400 mg/day
tolmetin (Tolectin [®])	400 mg PO TID	1,800 mg/day

Therapeutic alternatives are listed as Brand name[®] (generic) when the drug is available by brand name only and generic (Brand name[®]) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): hypersensitivity to meloxicam or any components of the drug product; history of asthma, urticarial, or other allergic-type reactions after taking aspirin or other NSAIDs; in the setting of coronary artery bypass graft (CABG) surgery
- Boxed warning(s): cardiovascular thrombotic events; gastrointestinal bleeding, ulceration, and perforation

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
OA or rheumatoid arthritis pain	5-10 mg PO QD	10 mg/day

VI. Product Availability

Capsules: 5 mg, 10 mg

VII. References

1. Meloxicam Prescribing Information. East Windsor, NJ: Novitium Pharma LLC Inc.; July 2024. Available at: <https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=ce9a8fd7-9bd2-4793-82f3-0fb8f0965d0f&type=pdf>. Accessed on August 13, 2024.

2. Micromedex® Healthcare Series [Internet database]. Greenwood Village, Colo: Thompson Healthcare. Updated periodically. Accessed August 1, 2024.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
4Q 2020 annual review: no significant changes; references reviewed and updated.	08.21.20	11.20
4Q 2021 annual review: no significant changes; references reviewed and updated.	06.25.21	11.21
Revised approval duration for Commercial line of business from length of benefit to 12 months or duration of request, whichever is less	09.27.21	02.22
4Q 2022 annual review: clarified failure of generic meloxicam “tablet”; added must use generic formulation language for brand Vivlodex; added references reviewed and updated. Template changes applied to other diagnoses/indications and continued therapy section.	07.28.22	11.22
4Q 2023 annual review: no significant changes; references reviewed and updated.	06.28.23	11.23
4Q 2024 annual review: removed brand Vivlodex from policy due to product discontinuation; clarified that this policy is applicable to meloxicam 5 mg and 10 mg capsules; references reviewed and updated.	07.15.24	11.24

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene[®] and Centene Corporation[®] are registered trademarks exclusively owned by Centene Corporation.